SCHEMBL14359459

SCHEMBL14359459

C[C@H]1CCCN1C(=O)C1CCCNC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A1 P30531 2/20 0.49
TSHR P16473 2/20 0.49
SLC6A11 P48066 1/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
SLC6A13 Q9NSD5 1/20 0.49
MAPT P10636 2/20 0.47
KMT2A Q03164 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ATM Q13315 1/20 0.47
CYP2D6 P10635 1/20 0.47
SMYD3 Q9H7B4 2/20 0.47
GAA P10253 2/20 0.43
NOS2 P35228 1/20 0.40
RECQL P46063 1/20 0.39
HPGD P15428 1/20 0.38
PLAT P00750 1/20 0.36
DPP4 P27487 3/20 0.35
FAP Q12884 2/20 0.35
DPP8 Q6V1X1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2996986 0.92 SMYD3 (0.42) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL2996988 0.92 SMYD3 (0.42) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL2996984 0.92 SMYD3 (0.42) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL3658061 0.92 SMYD3 (0.42) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL8449068 0.81 GAA (0.47) TSHRSMN1; SMN2MAPTKMT2AGAA
SCHEMBL20811837 0.81 SLC6A1 (0.46) SLC6A1TSHRSLC6A11LMNASMN1; SMN2
SCHEMBL15730093 0.81 GAA (0.64) TSHRLMNASMN1; SMN2MAPTKMT2A
SCHEMBL15730586 0.81 GAA (0.64) TSHRLMNASMN1; SMN2MAPTKMT2A
SCHEMBL6185245 0.81 GAA (0.64) TSHRLMNASMN1; SMN2MAPTKMT2A
SCHEMBL30525034 0.79 SLC6A1 (0.56) SLC6A1TSHRSLC6A11LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265289-A1 2-Aminopyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-11-15 US disclosed
US-20070265289-A1 2-Aminopyrimidine Derivative ASTELLAS PHARMA INC. (JP) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265289-A1 2-Aminopyrimidine Derivative NFKBIA, IKBKG, NFKB2 SLC6A1 4857/4885TSHR 4787/4885SLC6A11 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.